---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-24-000010"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:43:15.053073+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio reports Q4 2023 net loss of $42.2M, cash $417.9M; pipeline on track

## Summary
- Q4 net loss $42.2M ($1.59 per share); full-year net loss $163.6M ($6.08 per share).
- Cash & investments $417.9M at Dec 31, 2023 (down from $584.2M year-end 2022); runway through 2026.
- R&D spend $33.5M in Q4, up 43% YoY, driven by rosnilimab, ANB032, and ANB033 manufacturing.
- ANB032 Phase 2b atopic dermatitis top-line data expected by year-end 2024; rosnilimab RA data mid-2025, UC data H1 2026.
- IND filings for ANB033 (anti-CD122) in Q2 2024 and ANB101 (BDCA2) in H2 2024; ANB101 licensed for $7M upfront.

## SEC filing metadata
- accession: 0001370053-24-000010
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000010/0001370053-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000010/anab-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-24-000010
- JSON: https://secwatch.observer/filing/0001370053-24-000010.json
- Plain text: https://secwatch.observer/filing/0001370053-24-000010.txt

## Key facts
- Earnings Releases
  ANAPTYSBIO, INC reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 11, 2024, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000010/0001370053-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.